1 million Euro António Champalimaud Vision Award recognises revolutionary treatment of devastating blinding diseases
The 2014 António Champalimaud Vision awardees were honoured today, September 10th, at a ceremony held at the Champalimaud Centre for the Unknown in Lisbon, Portugal.
This year’s Vision Award was given to seven researchers for the development of Anti-Angiogenic Therapy for Retinal Disease. This award confirms the importance of the research work developed by Napoleone Ferrara, Joan W. Miller, Evangelos S. Gragoudas, Patricia A. D’Amore, Anthony P. Adamis, George L. King e Lloyd Paul Aiello, which resulted in the discovery of an effective therapy for the treatment of two of the leading causes of vision loss and blindness in the world - age-related macular degeneration and diabetic retinopathy.
But more than the result, the award recognises the scientific process that led to it, and that had an impact not only in ophthalmology but also in oncology. The work of this year’s awardees covers the entire research process, from the identification of the molecule in cancer investigation context, to the elucidation of its role in retinal-vascular disease in animals and humans, to the experimental evaluation of an inhibitor and its final application in the treatment of affected patients.
The clinical value of anti-VEGF therapy has been well established through a large number of clinical trials in patients with neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusions, offering a real hope to millions of affected individuals around the world.
The António Champalimaud Vision Award will contribute to the continuation of the remarkable efforts of these scientists, helping to create and develop new applications and research lines in favor of science and quality of life.